Astellas Submits Fezolinetant New Drug Application to U.S. FDA

Application targets treatment of moderate to severe vasomotor symptoms associated (VMS) with menopause TOKYO, June 23, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news